Skip to main content

Refractory Partial Seizures

Neurology
0
Pipeline Programs
1
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.

$26.9B marketMature→ Stable30 products15 companies

Key Trends

  • Extreme market concentration: 68% of spending driven by one FXa inhibitor product
  • Psychiatric and migraine therapies emerging as secondary growth drivers
  • High clinical trial activity (8,279 trials) signals continued pipeline development

Career Verdict

Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISStable
$18.3B
Bristol Myers Squibb·Launch15.0yr
$1.8B
#3BRILINTAStable
$692M
AstraZeneca·Peak10.2yr
#4NUPLAZIDStable
$596M
$530M
Johnson & Johnson·Peak15.5yr

Drug Class Breakdown

FXa Inhibitors (anticoagulant)
$18.3B(68%)

market-defining single product

Dopamine/Serotonin Antagonists (psychiatric)
$2.4B(9%)

stable mature class

P2Y12 Receptor Antagonists (antiplatelet)
$692M(3%)

niche but stable

5-HT2A Inverse Agonists (psychiatric)
$596M(2%)

specialty indication focus

CGRP Receptor Antagonists (migraine)
$931M(3%)

emerging growth segment

Immunomodulators (MS)
$747M(3%)

stable with LOE risk

Other mechanisms
$2.6B(10%)

diverse small products

Career Outlook

Stable

Neurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.

Breaking In

Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.

For Experienced Professionals

Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.

In-Demand Skills

Medical Science Liaisons (MSL) for specialist engagementClinical trial operations expertisePsychiatric/neurodegenerative disease educationRegulatory affairs (given patent cliff activity)Commercial strategy around branded/generic transitions

Best For

Medical Science LiaisonCommercial Brand Manager (anticoagulant/psychiatric franchises)Clinical Operations ManagerRegulatory Affairs SpecialistClinical Development Manager (CGRP/immunomodulator pipelines)

Hiring Landscape

$100K-$199K

Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.

4,186
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

762Growing
434Stable
302Stable

By Department

Commercial(23%)
$169K
Clinical Operations(11%)
$132K
Engineering(8%)
$199K
IT(4%)
$100K
Manufacturing(3%)
$170K

Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Eisai
EisaiChina - Liaoning
5 programs
E2007PHASE_21 trial
perampanelPHASE_21 trial
E2007PHASE_31 trial
E2007PHASE_31 trial
perampanelPHASE_31 trial
Active Trials
NCT00849212Completed30Est. Nov 2009
NCT00903786Completed21Est. Oct 2016
NCT00699972Completed390Est. Oct 2010
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Eisaiperampanel
EisaiE2007
EisaiE2007
Eisaiperampanel
EisaiE2007

Clinical Trials (5)

Total enrollment: 1,542 patients across 5 trials

Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Start: Aug 2008Est. completion: Jan 2010712 patients
Phase 3Completed

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Start: May 2008Est. completion: Jan 2011389 patients
Phase 3Completed

Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Start: Apr 2008Est. completion: Oct 2010390 patients
Phase 3Completed

A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)

Start: Jun 2009Est. completion: Oct 201621 patients
Phase 2Completed

An add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs)

Start: Apr 2009Est. completion: Nov 200930 patients
Phase 2Completed

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.